At the same time, it is worth noting that these results remain preliminary, with other trials reporting better clinical outcomes and higher tumor-infiltrating lymphocytes (TILs) in HCC patients with TP53 mutations (74, 75). Here, TP53 is linked to hepatocellular carcinoma.